NAVB Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Navidea Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.001 |
| 52 Week High | US$0.13 |
| 52 Week Low | US$0.000001 |
| Beta | 1.45 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -98.57% |
| 33 Year Change | -99.91% |
| 5 Year Change | -99.90% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| NAVB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.5% |
| 1Y | -98.6% | 15.6% | 30.7% |
Return vs Industry: NAVB underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: NAVB underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| NAVB volatility | |
|---|---|
| NAVB Average Weekly Movement | 62.4% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NAVB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NAVB's weekly volatility has decreased from 909007% to 62% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 13 | n/a | www.navidea.com |
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
Navidea Biopharmaceuticals, Inc. Fundamentals Summary
| NAVB fundamental statistics | |
|---|---|
| Market cap | US$99.99k |
| Earnings (TTM) | -US$8.81m |
| Revenue (TTM) | US$610.00 |
163.9x
P/S Ratio0.0x
P/E RatioIs NAVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAVB income statement (TTM) | |
|---|---|
| Revenue | US$610.00 |
| Cost of Revenue | US$50.04k |
| Gross Profit | -US$49.43k |
| Other Expenses | US$8.77m |
| Earnings | -US$8.81m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.088 |
| Gross Margin | -8,102.62% |
| Net Profit Margin | -1,444,993.44% |
| Debt/Equity Ratio | -41.9% |
How did NAVB perform over the long term?
See historical performance and comparison